#84 The Cutting Edge of Mind Bending, Mind Tech: Exploring the Intersection of AI, Brain Computers, and Precision Psychiatry with Investors Daniel Weiss Pick and Sonia
Mental Health Today - A podcast by Ken Stearns
Daniel and Sonia are both deeply involved in the mental health space, particularly in the tech and innovation aspects. They are part of a fund that invests in startups focused on brain health and mental health. Their portfolio includes various companies working in areas like psychedelics, drug development, neuromodulation, brain-computer interfaces, and precision psychiatry. They have invested in approximately 22 companies, which is a significant undertaking due to the diverse nature of their investments. Their efforts involve extensive research, interaction with startups, research institutes, fellow investors, and fundraising from individuals interested in contributing to the mental health space. The discussion touches on the nature of investors in the mental health and brain health sectors. While the risk associated with startups in these areas is significant, they believe in the potential for innovation to make a substantial impact on mental health. They acknowledge that not all startups will succeed, but the hope is that the successful ones will outweigh the losses, ultimately benefiting those suffering from mental health conditions. They also delve into the topic of investing in psychedelics. The conversation explores the various theories regarding how psychedelics might positively impact mental health and the potential for modifying psychedelics to harness their therapeutic effects without hallucinations. Sonia and Daniel discuss their favorite recent developments among the companies they've invested in. Sonia highlights a precision psychiatry company that is working on using AI to analyze fMRI brain scans remotely, which could lead to more precise diagnostics for mental health conditions. Daniel shares exciting news about companies developing compounds derived from psychedelics that focus on enhancing neuroplasticity without hallucinogenic effects. They also touch on their unique approach to investing in the mental health space, which combines traditional and innovative solutions. While there are other investors in mental health and tech, they feel their specific combination of interests and focus is unique. The conversation ends with a reflection on the importance of mental health and how the emerging innovations in the field may help address the global mental health crisis.